SLD — Saluda Medical Income Statement
0.000.00%
Last trade - 00:00- AU$2.85bn
- AU$3.14bn
- $70.36m
- 10
- 36
- 63
- 27
Annual income statement for Saluda Medical, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 22.2 | 51.7 | 70.4 |
| Cost of Revenue | |||
| Gross Profit | 4.04 | 23.1 | 32.8 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Unusual Expense / Income | |||
| Total Operating Expenses | 114 | 151 | 209 |
| Operating Profit | -91.6 | -99.1 | -139 |
| Total Net Non Operating Interest Income / Expense | |||
| Other Net Non Operating Costs | |||
| Net Income Before Taxes | -91.5 | -97.6 | -149 |
| Provision for Income Taxes | |||
| Net Income After Taxes | -92.2 | -97.8 | -149 |
| Net Income Before Extraordinary Items | |||
| Net Income | -92.2 | -97.8 | -149 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -92.2 | -97.8 | -149 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -0.367 | -0.388 | -0.539 |